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Clear cell sarcoma of tendons and aponeuroses (CCS), also
known as malignant melanoma of soft parts, represents a distinct
clinicopathologic entity first described by Enzinger in 1965
(Enzinger, 1965). CCS usually presents as a slowly growing
and frequently painful soft tissue mass, occuring primarily in
adolescents and young adults, with a predilection for the lower
extremeties, especially around the ankle and knee, although the
overall anatomic distribution is wide (Chung and Enzinger,
1983). The tumours are usually intimately associated with fascial
or tendoaponeurotic structures but may regularly involve the
subcutis and dermis by direct extension. Radiologically the lesion
is often mistaken for a benign process (De Beuckeleer et al,
2000). CCS is characterized by repeated local recurrence and,
with time, metastasizes primarily to lymph nodes, the lungs and
bone; 5 and 10 year survival is variable but is in the order of 50%
and 10–20%, respectively. Surgery remains the mainstay of
therapy while the efficacy of adjuvant radiotherapy and/or
chemotherapy remains uncertain. 
Histopathologically, CCS displays a number of features
exhibiting a broad morphologic overlap with conventional malig-
nant melanoma, including melanin synthesis and expression of
HMB-45 and S-100 protein (Kindblom et al, 1983; Mooi et al,
1995; Graadt van Roggen et al, 1998). In addition vimentin and,
occasionally, low levels of low molecular weight cytokeratins are
also variably present (Mooi et al, 1995). Ultrastructurally, features
of melanocytic differentiation are identifiable in both tumours in-
cluding the presence of an external lamina and cytoplasmic 
premelanosomes in various stages of maturation (Kindblom et al,
1983). 
Cytogenetic analysis of CCS has identified the presence of an
apparently tumour-specific balanced translocation involving chro-
mosomes 12 and 22 in more than 50% of cases (Epstein et al,
1984; Bridge et al, 1990, 1991; Peulvé et al, 1991; Fletcher, 1992;
Reeves et al, 1992; Rodriguez et al, 1992; Speleman et al, 1992;
Stenman et al, 1992; Travis and Bridge, 1992; Mrozek et al, 
1993; Limon et al, 1994; Zucman et al, 1993; Nedoszytko et 
al, 1996; Speleman et al, 1997; Graadt van Roggen et al, 1998).
This translocation results in the fusion of a portion of the
Activating Transcription Factor gene (ATF-1) on the long arm of
chromosome 12(12q13.1–13.2) and the Ewing’s sarcoma onco-
gene (EWS) on chromosome 22 (22q13) (Zucman et al, 1993). To
date no significant study has investigated the presence or absence
of this translocation in malignant melanoma in order to validate
the value of detection of this translocation in distinguishing
between translocation-positive CCS and metastatic melanoma in
the absence of a known primary tumour. Since the distinction
between these two entities may be of significant clinical 
importance, and since histomorphologic examination may not
always provide an unambiguous diagnosis, the presence of a
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(cyto)genetically detectable molecular genetic alteration to make
this distinction is very attractive. 
For this reason metastases of 25 primary cutaneous melanomas
as well as 8 well characterized melanoma cell lines (5 uveal and 
3 ocular) were analysed for the possible presence of the t(12;22)
(q13;q13) translocation using the reverse transcriptase polymerase
chain reaction (RT-PCR) and interphase fluorescent in situ
hybridization (FISH) using chromosome 12 (ATF-1) c.q. chromo-
some 22 (EWS) specific probes. 
MATERIALS AND METHODS 
Materials 
Snap frozen tissue samples stored at –80˚C, of melanoma meta-
stases from 25 patients with a known cutaneous malignant
melanoma, were retrieved from our archives. Histologic slides of
both the primary tumours and metastases were independently
reviewed by two pathologists (JFGvR and PCWH). Furthermore,
we obtained RNA from 5 uveal and 3 cutaneous melanoma cell
lines kindly provided by Dr Martine J Jager (de Waard-Siebinga 
et al, 1995). As a positive control for the RT-PCR and FISH
studies we used the SU-CCS-1 clear cell sarcoma cell line, cytoge-
netically proven to carry the t(12;22)(q13;q13) translocation,
generously provided by Dr O Delattre (Zucman et al, 1993). Snap
frozen tissue from 2 cases of CSS in our archives carrying the
t(12;22)(q13;q13) translocation as detected using RT-PCR (see
below) were used as additional positive controls. MDA-MB-134, a
breast cancer cell line was used as a negative control. 
Methods 
RNA and DNA analysis 
Total RNA was extracted from the various cell lines (4.5 ´ 106
cells per extraction) using TRIzol (Gibco BRL Life Technologies,
Gaithersburg, MD, USA), according to the manufacturer’s recom-
mendation. RNA from snap frozen tumour tissue was isolated
using TRIzol after cutting 20 sections of 20 mm on a cryostat-
microtome. Between cutting of individual specimens, the micro-
tome blade was thoroughly cleaned with 70% ethanol to avoid
cross contamination. The RNA concentration and purity was
determined by measuring the absorption at 260 and 280 nm spec-
trophotometrically. cDNA was made from total RNA using AMV-
reverse transcriptase (Boehringer Mannheim, Germany). One to
two mg of total RNA was used for reverse transcription. The RNA
was added to a mixture of 100 ng 15-mer primer pDT (Boehringer
Mannheim, Germany), 1U RNAsin, 1mM dNTP, 100 mM Tris-
HCL pH of 8.3, 80 mM KCL, 12 mM MgCl2, 2 mM DTT and 5 U
AMV-reverse transcriptase up to a volume of 20 ml. The tubes
were incubated at 39˚C for one hour. The tubes, now containing
cDNA, were stored at –20˚C or used directly. One ml of the cDNA
was used for amplification. The cDNA was added to a mixture
containing 30 pmol of a forward primer in exon 8 of EWS desig-
nated as DO3 (5¢-ATCGTGGAGGCATGAGCA-3¢) and a reverse
primer in ATF-1 designated as DO4 (5¢-ACTCCATCTGTGC-
CTGGACT-3¢) (Life Technologies, Gaithersburg, MD, USA),
0.04 mM dNTP, 50 mM KCl, 10 mM Tris (pH 8.3), 0.2 mg ml–1
bovine serum albumin (BSA), 2 mM MgCl2 and 1 U Ampli-
TaqGold (PE Biosystems) up to a volume of 50 ml. Subsequently
PCR-reactions were performed using conditions deduced from a
Robocycler gradient 96 experiment (Stratagene). Optimal PCR
conditions were 33 cycles, with each cycle consisting of denatura-
tion at 94˚C for 30 sec, annealing at 65˚C for 1 min and elongation
at 72˚C for 1 min. Optimal MgCl2 concentration appeared to be 
2 mM. Transcripts of the housekeeping gene for hypoxanthine
phosphoribosyl transferase (HPRT) were amplified simultane-
ously under the same conditions as a control for RNA integrity.
HPRT cDNA was amplified with primers hum 1 (5¢-ACCG-
GCTTCCTCCTCCTGAGCAGTC-3¢) and hum2 (5¢-AGGACTC-
CAGATGTTTCCAAACTCAACTT-3¢). cDNA from a breast
cancer cell line (MDA-MB-134) was used as a negative control for
the RT-PCR translocation. cDNA from the cultured CCS cell line,
with cytogenetically confirmed t(12;22)(q13;q13), was included 
in each test as a positive control for the EWS/ATF-1 fusion 
transcript. Water was used as a negative control to exclude the
possibility of contamination of reagents. Thermal cycling was
performed in a DNA Thermal cycler Type 480, Perkin Elmer. 
RT-PCR products were stained with ethidium bromide and
visualized on a 1.5% agarose gel. Sequence analysis was
performed on an AB1 377 automatic sequencer using a Big
Dyeterminator sequencing kit (PE Biosystems). 
Fluorescent in situ hybridization 
Interphase FISH was performed on nuclei as described
(Vaandrager et al, 1996). The nuclei were isolated from sections 
of frozen tissue of 40 mm. Nuclei isolated from the SU-CCS-1 cell
line, with a proven t(12;22) translocation, were used as a positive
control. 
The Cosmids G9 and CCS2.2 (generously provided by 
Dr Speleman) (Speleman et al, 1997), corresponding to the
5¢region of EWS and 3¢ region of ATF-1 respectively, were used as
probes and labelled by a standard nick-translation method. Cosmid
G9 was labelled with biotin-16-dUTP and CCS2.2 with digoxine-
11-dUTP (Roche, Basle, Switzerland). Slides were hybridized
overnight with hybridization solution containing 50% formamide,
10% dextran sulphate, 50 mM sodium phosphate, 3 ng ml–1 of each
probe and a 50-fold excess of human Cot-1 DNA. Hybridization
and immunofluorescence detection were performed as described
(Vaandrager et al, 1996). 100 nuclei of each hybridization were
analysed for colocalization of both signals. The t(12;22) transloca-
tion was diagnosed when colocalization of signal was seen in more
than 10% of the nuclei studied. 
RESULTS 
None of the 25 melanoma metastases and 8 melanoma cell 
lines carried the t(12;22)(q13;q13) translocation as analysed by
RT- PCR. The SU-CCS-1 cell line with a cytogenetically proven
t(12;22)(q13;q13) translocation, as well as two clear cell sar-
comas, demonstrated the EWS/ATF-1 fusion transript using 
RT- PCR. 
The EWS/ATF-1 fusion transcript in all positive control 
cases studied yields a 241 base pair (bp) PCR product (Figure 1),
as expected from previous studies (Zucman et al, 1993). 
This is the result of a fusion between codon 325 of the EWS 
gene and codon 65 of ATF-1. The chimaeric breakpoint was
confirmed by sequence analysis of the RT-PCR product 
(data not shown). RNA integrity of all negative cases was
assessed by RT-PCR amplification of the housekeeping gene
HPRT, which generates a 747 bp PCR product. In all tumours
and cell lines tested HPRT was clearly and unambiguously
demonstrable.FISH on interphase nuclei was performed to confirm the RT-
PCR results (Figure 2). None of the melanomas tested carried the
t(12;22)(q13;q13) translocation not detectable using RT-PCR,
while the SU-CCS-1 cell line and the two CCS with the, by RT-
PCR detectable, t(12;22)(q13;q13) translocation showed colocal-
ization of the EWS and ATF probes. 
DISCUSSION 
In the last decade it has become increasingly apparent that specific
soft tissue tumours may be associated with tumour-specific
translocations (Fletcher et al, 1991; Ladanyi, 1995; Graadt van
Roggen et al, 1999). Tumour-specific (cyto)genetic alterations
may be particularly useful in the diagnostic setting where the
histopathologic features and conventional ancillary techniques are
insufficient to allow an unambiguous diagnosis (e.g. in the differ-
ential diagnosis of small round blue cell tumours), and where an
accurate histopathologic diagnosis will significantly influence the
therapeutic modalities employed. In the appropriate clinico-
pathologic setting the relevant differential diagnosis with CCS and
metastatic malignant melanoma without a known primary may
occasionally be problematic due to the broad morphologic overlap
which exists between these two tumours. Nevertheless, an accurate
histopathologic diagnosis is of paramount importance considering
the different therapeutic options which may be applicable in the
individual clinical setting when considering a primary soft tissue
tumour versus a metastatic process. 
In CCS a t(12;22)(q13;q13) translocation has been characterized
and appears to be specific for this sarcoma (Zucman et al, 1993;
Ladanyi, 1995; Speleman et al, 1997; Graadt van Roggen et al,
1999). Cytogenetic studies of melanomas, while identifying
numerous non-specific and variable chromosomal alterations,
have not as yet identified the t(12;22) translocation within this
tumour (Pedersen et al, 1985; Graadt van Roggen et al, 1998;
Piepkorn, 2000). At a molecular level however, data is beginning
to support the probable involvement of the CDKN2A tumour-
suppressor locus and other loci in tumorigenesis (Castellanol and
Parmiani, 1999; Piepkorn, 2000). 
Consequently, detection of the t(12;22) translocation by molec-
ular biological techniques (eg. RT-PCR or FISH) may be very
useful in distinguishing CCS and metastatic melanoma in the
appropriate clinical setting. 
Two variant hybrid t(12;22) transcripts have been identified.
The breakpoints differ by 40 amino acids, but since both chimaeras
contain essentially the same regions the biological behaviour of
these molecular variants is not expected to be dissimilar
(Speleman et al, 1997; Graadt van Roggen et al, 1998). 
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Figure 1 Reverse transcriptase polymerase chain reaction (RT-PCR) assay
used to screen the melanoma metastases and melanoma cell lines for the
t(12;22) translocation. Following RT-PCR, the reaction products were run on
a 1.5% agarose gel and visualized using ethidium bromide. Lane 1: 100 bp
marker ladder, lane 2: HPRT amplification to control for RT-PCR reaction,
lane 3: SU-CCS-1 positive control cell line carrying t(12;22) translocation,
lane 4: ‘no template’ negative control, lane 5: melanoma metastasis, lane 6:
clear cell sarcoma 
AB
Figure 2 Fluorescent in situ hybridization performed to validate the reverse transcriptase polymerase chain reaction results described under ‘Results’
Arrowheads represent EWS probe on chromosome 22; short-tailed arrows represent ATF-1 probe on chromosome 12. (A) Two copies of both chromosomes 
12 and 22 are visualized using the respective probes for ATF-1 and EWS (see methods). (B) Colocalization (long-tailed arrow) of both probes confirming the
presence of the t(12; 22) translocation in the SU-CCS-1 cell line used as positive control538 SM Langezaal et al 
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The first hybrid consists of EWS [exon 8, (codon 325)/ATF-1
(codon 65)], which gives a PCR-fragment of 241 bp using our
primer constructs. The second hybrid consist of EWS [exon 10, 11
junction (codon 349)/ATF-1 (codon 110)], which would give a
PCR-fragment of 178 bp with our primer constructs (Zucman 
et al, 1993; Speleman et al, 1997; Graadt van Roggen et al, 
1998). 
To date no systematic investigations of the presence or absence
of this translocation in malignant melanoma have been published,
which was the main motive for initiating this analysis. Our results
clearly demonstrate the absence of the t(12;22)(q13;q13) in any of
the melanoma samples tested, in the presence of positive and negat-
ive controls. Although RT-PCR is sensitive and reliable, there is a
possibility that additional, as yet undescribed, variant EWS/ATF-1
translocations might be missed if the chromosomal breakpoints lie
outside the primer set used in this study. Consequently FISH
studies were performed, as a means of verifying the negative 
RT-PCR results, and to identify any possible additional chromo-
somal EWS/ATF-1 rearrangements. The FISH results however
confirmed our RT-PCR data and failed to identify any additional
translocations involving EWS and ATF-1. 
In CCS as well as the SU-CCS-1 cell line the t(12;22) transloca-
tion was clearly detected with RT-PCR, as well as FISH. 
Despite the morphologic similarity between CCS and metastatic
melanoma at a light microscopic and ultrastructural level, clearly
these tumours are distinct entities at the molecular genetic level
supporting the supposition that CCS represents a separate and
distinct entity. Nevertheless, the t(12;22)(q13;q13) translocation
only appears to be detectable in 50–70% of cases of clear cell
sarcoma. Therefore the absence of a detectable EWS/ATF-1
rearrangement may on occasion lead to the erroneous exclusion of
a translocation negative CCS in the above mentioned clinicopatho-
logical differential diagnosis. This needs to be borne in mind when
the discussed differential diagnosis between clear cell sarcoma and
metastatic melanoma arises and resolution will require review of
the case in the context of the complete clinicopathologic setting. 
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